Researchers at the University of Montana and the University of Washington are preparing to launch the first human trials of vaccines designed to block the effects of fentanyl and heroin. The milestone follows preclinical studies showing the vaccines could prevent the drugs from reaching the brain — potentially stopping overdose deaths and helping people in recovery avoid relapse.
At a glance
- Fentanyl vaccine: Preclinical trials in rats and pigs showed the vaccine produced antibodies that bind to fentanyl in the bloodstream, preventing it from crossing the blood-brain barrier and reaching opioid receptors in the brain.
- Human trials timeline: Phase 1 trials are expected to begin in early 2024 C.E. at Columbia University in New York City, testing escalating doses in people who already use opioids to confirm the vaccine is safe.
- Opioid overdose deaths: Tens of thousands of people in the U.S. died from opioid overdoses in 2021 C.E. alone, according to the National Institute on Drug Abuse, with opioid-related deaths rising steadily since at least 1999 C.E.
How the vaccine works
The mechanism is straightforward in principle, even if the science behind it is not. When a vaccinated person encounters fentanyl, antibodies generated by the immune system bind to the drug molecules — acting, in the words of University of Washington professor Marco Pravetoni, “kind of like a sponge.”
That binding keeps the drug in the bloodstream rather than letting it cross into the brain. With no access to the brain’s opioid receptors, fentanyl produces no high and, crucially, no respiratory depression — the slowed breathing that makes an overdose fatal.
“Following vaccination, doses of fentanyl had ‘no effects’ on these animals because it doesn’t reach the receptor,” Jay Evans, director of the University of Montana Center for Translational Medicine and co-founder of the corporate partner Inimmune, explained. “And then it just gets recycled out of the body.”
Critically, the vaccine is designed to be specific. Preclinical studies showed it does not interfere with methadone, buprenorphine, naltrexone, or naloxone — all medications used to treat opioid addiction or reverse overdose. Surgery involving non-fentanyl anesthetics would also remain unaffected.
A crisis decades in the making
Fentanyl was first introduced in the 1960s C.E. as an intravenous anesthetic. It is roughly 100 times more potent than morphine. Outside a controlled clinical setting, even a few grains of the synthetic version — commonly sold as powder or mixed into other street drugs — can be lethal.
The concept of vaccinating against opioids dates back to the 1970s C.E., when researchers showed it was possible to vaccinate non-human primates and stop them from self-administering heroin. That line of research stalled, and interest only began to revive in the 1990s and early 2000s C.E. with vaccines targeting nicotine and cocaine — none of which reached the market.
The renewed push owes much to the NIH HEAL Initiative — the National Institutes of Health’s Helping to End Addiction Long-term program — which has directed tens of millions of federal dollars toward this research. Evans says his work is 100 percent NIH-funded. The preclinical findings were published as a pair of papers in the journal npj Vaccines.
Why recovery is the target
If the trials succeed and the vaccine eventually reaches patients, Evans has a specific use case in mind: the first two years after someone enters rehab.
“Patients who are addicted to opioids and want to quit and are going through rehab — their chance of relapse in the first two years is 80 to 90 percent,” he said. “If they can get past those two years, their chance of staying clean is very good.”
The goal is to keep antibody levels high during that high-risk window, then allow them to wane naturally over time — so that a person who needed fentanyl as a legitimate painkiller a decade later would still have access to it.
Pravetoni also hopes the vaccine format could help reduce the stigma that keeps many people from seeking treatment in the first place. Because vaccines are a familiar, widely accepted medical intervention, they may “open up more avenues” for people who feel shame about addiction-specific treatments.
Real promise, real limits
The researchers are careful not to overstate what the vaccine can do. It targets only fentanyl and fentanyl analogues, along with heroin — someone vaccinated against those drugs could still overdose on other substances. Evans acknowledged that some people might try to compensate by escalating to other drugs to chase a high.
There is also the straightforward matter of time. Phase 1 trials test safety, not effectiveness. Phase 2 and 3 trials — which would determine optimal dosing and allow FDA evaluation — lie years down the road. “It takes a long time — years — to get to a final approved product,” Evans noted.
Even in a best-case scenario, a vaccine would be one tool among many. Addressing the opioid crisis also requires changes to how doctors prescribe opioids, stronger public education, and a sustained cultural shift around how addiction is perceived and treated. “You need a toolbox of tools to help this crisis,” Evans said. “The vaccine alone isn’t going to solve it.”
The broader healthcare system’s dependence on opioid-based pain management remains a structural challenge no vaccine can fix on its own — a problem Evans described as part of an “immensely complex picture.”
Read more
For more on this story, see: Futurism / Neoscope
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
